Jefferies raised the firm’s price target on Quest Diagnostics (DGX) to $225 from $220 and keeps a Buy rating on the shares following a beat on sales and EPS, led by strong organic volumes. FY26 guidance for sales and EPS also moved higher reflecting the Q1 beat, notes the analyst.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Midday Fly By: Apple names new CEO, Amazon ups investment in Anthropic
- Early notable gainers among liquid option names on April 21st
- Quest Diagnostics: Sustained Volume Growth and Upgraded Revenue Outlook Justify Premium Valuation and Buy Rating
- Quest Diagnostices reports Q1 adjusted EPS $2.50, consensus $2.37
- Quest Diagnostics raises FY26 adjusted EPS view to $10.63-$10.83